ERR2208888
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- NOTCH_SIGNALING+0.300
- DNA_REPAIR+0.200
- HEDGEHOG_SIGNALING+0.200
- ADIPOGENESIS+0.100
- APICAL_SURFACE+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- APOPTOSIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932822 | — | — | 0.885 |
| 2 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.883 |
| 3 | BS_P39SQPTS | Embryonal tumors | — | 0.881 |
| 4 | SRR12696755 | — | — | 0.876 |
| 5 | MNG147 | — | — | 0.874 |
| 6 | MNG86 | — | — | 0.873 |
| 7 | SRR5088851 | — | — | 0.873 |
| 8 | SRR8518365 | — | E | 0.872 |
| 9 | 20050169.TNBC | — | E | 0.871 |
| 10 | C3N-02283 | — | cohortMD1 | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |